Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Study Links Omega-3 Fatty Acids and Prostate Cancer Risk

July 20, 2013
By Anna Azvolinsky
Article

A large and prospective study shows that a high concentration of omega-3 fatty acids is linked to a higher risk of aggressive prostate cancer.

A large and prospective study shows that a high concentration of omega-3 fatty acids is linked to a higher risk of aggressive prostate cancer. Alan Kristal, professor of epidemiology at the school of Public Health at the Fred Hutchinson Cancer Center in Seattle, and colleagues show that high concentrations of fatty acids from nutritional supplements-eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA)-was linked to an overall 43% higher relative risk of prostate cancer. The results are published in the Journal of the National Cancer Institute.

The study also showed that men with high concentrations of these fatty acids had a 44% higher risk of low-grade prostate cancer and a 71% higher risk of high-grade prostate cancer compared with men who had the low levels of these fatty acids in their blood.

"We've shown once again that use of nutritional supplements may be harmful," said Kristal in a press release.

Still, the results do not show a direct cause-and-effect relationship. More studies are needed to confirm this result.

The researchers analyzed samples and followed patients from men who were part of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Participants were randomized to selenium, vitamin E, the combination of both supplements, or to placebo to test whether these supplements reduce prostate cancer risk. The study showed that while selenium had no effect, vitamin E increased the risk of prostate cancer. More than 35,000 men in North America were randomized in the study.

For the current analysis, Kristal and colleagues analyzed 834 men who had diagnosed with primary prostate cancer (including 156 who had high-grade disease) and 1,393 men randomly selected from the SELECT study.

The study results corroborate a study published by the same authors in 2011 that showed high levels of DHA in the blood also increased the risk of high-grade prostate cancer. That analysis used samples from the Prostate Cancer Prevention Trial.

According to the authors, these two studies together demonstrate a role of omega-3 fatty acids in the occurrence of prostate cancer, but do not address whether these fatty acids have a role in progression in men already diagnosed with prostate cancer.

Another recent meta-analysis on the effect of omega-3 supplementation on cardiovascular disease was published in JAMA. While several studies showed that omega-3 supplements could prevent stroke, heart attack, and other cardiac-related death, the compiled data did not come to the same conclusion, finding that omega-3 supplements did not show a benefit.

“Whereas a lack of coherent mechanism had led the authors of previous studies, including us, to consider findings suspect, their replication here strongly suggest that long-chain omega-3 poly-unsaturated fatty acids do play a role in enhancing prostate tumorigenesis,” state the authors in the discussion of their publication.

The results are surprising as omega-3 fatty acids are known to have anti-inflammatory effects and have been thought to have positive effects on health and because inflammation has been shown to promote tumorigenesis. In fact, poly-unsaturated fatty acids have been promoted to prevent cancer and cardiovascular risks.

More research is needed to understand whether high levels of omega-3’s do indeed contribute to prostate cancer tumorigenesis and the mechanism for how this occurs.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Related Content

The FDA did not expand the indication to include patients with non-homologous recombination-repair gene-mutated castration-resistant prostate cancer.

FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC

Roman Fabbricatore
June 18th 2025
Article

The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Machine Learning Approach May Predict Outcomes in RCC

Kristie L. Kahl
June 4th 2025
Article

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer

Roman Fabbricatore
June 3rd 2025
Article

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.


Niraparib Plus Abiraterone/Prednisone Extends rPFS in HRR-Altered mCSPC

Niraparib Plus Abiraterone/Prednisone Extends rPFS in HRR-Altered mCSPC

Silas Inman
June 3rd 2025
Article

Niraparib plus abiraterone acetate and prednisone significantly reduced the risk of symptomatic progression in patients with BRCA-mutated metastatic castration-sensitive prostate cancer.

Related Content

The FDA did not expand the indication to include patients with non-homologous recombination-repair gene-mutated castration-resistant prostate cancer.

FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC

Roman Fabbricatore
June 18th 2025
Article

The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Machine Learning Approach May Predict Outcomes in RCC

Kristie L. Kahl
June 4th 2025
Article

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer

Roman Fabbricatore
June 3rd 2025
Article

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.


Niraparib Plus Abiraterone/Prednisone Extends rPFS in HRR-Altered mCSPC

Niraparib Plus Abiraterone/Prednisone Extends rPFS in HRR-Altered mCSPC

Silas Inman
June 3rd 2025
Article

Niraparib plus abiraterone acetate and prednisone significantly reduced the risk of symptomatic progression in patients with BRCA-mutated metastatic castration-sensitive prostate cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.